文献速递免疫规划

2至23月龄婴幼儿接种四价脑膜炎球菌结合疫苗的安全性

Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old.
PubMed 文献 · Vaccine · 2019-10-21

本研究纳入2014年7月至2017年6月期间在Kaiser Permanente南加州医疗系统接种MenACWY-CRM的2-23月龄婴幼儿138例,通过电子健康记录检索接种后6个月内的急诊和住院就诊及诊断。结果显示急诊就诊发生率为0.6/人年(95%CI:0.5-0.8),住院为0.4/人年(95%CI:0.3-0.5),急诊转住院为0.1/人年(95%CI:0.1-0.3),29.0%的受种者出现急诊或住院诊断,发热和急性上呼吸道感染最常见,47例诊断中46例发生于高危条件婴幼儿。数据未提示MenACWY-CRM存在安全性担忧。

要点

  • 138名2-23月龄婴幼儿接种MenACWY-CRM,59.4%为非裔美国人,66.7%仅接种一剂。
  • 急诊就诊发生率0.6/人年(95%CI:0.5-0.8),住院0.4/人年(95%CI:0.3-0.5)。
  • 发热和急性上呼吸道感染最常见,47例诊断中46例发生于高危条件婴幼儿。

核心结论

  • 这项描述性观察研究的数据未提示MenACWY-CRM在2-23月龄有接种指征婴幼儿的临床使用中存在安全性担忧。

研究设计与样本

  • 描述性观察研究,纳入2014年7月至2017年6月在Kaiser Permanente南加州医疗系统接种MenACWY-CRM的2-23月龄婴幼儿138例。
  • 通过电子健康记录检索每次接种后6个月内的急诊和住院就诊及相关诊断。

主要发现

  • 138例受种者中59.4%为非裔美国人,66.7%仅接种一剂。
  • 42.0%的婴幼儿有高危条件(解剖/功能性无脾或DiGeorge综合征),54.3%有旅行指征。
  • 急诊就诊发生率为0.6/人年(95%CI:0.5-0.8),住院为0.4/人年(95%CI:0.3-0.5),急诊转住院为0.1/人年(95%CI:0.1-0.3)。
  • 29.0%的受种者在急诊或住院场所出现 incident 诊断。
  • 发热和急性上呼吸道感染是最常见诊断,47例诊断中46例发生于高危条件婴幼儿。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The quadrivalent meningococcal conjugate vaccine MenACWY-CRM is recommended for 2-23 month-old infants/toddlers at increased risk for meningococcal disease. This study adds to the current knowledge of MenACWY-CRM safety among this age group in a clinical care setting. METHODS: Kaiser Permanente Southern California members aged 2-23 months who received MenACWY-CRM between July 2014 and June 2017 were included. Electronic health records were searched for emergency department (ED) and hospitalization encounters, and diagnoses associated with these visits up to 6 months after each dose. RESULTS: There were 138 infants/toddlers who received MenACWY-CRM, with 59.4% being African American and 66.7% receiving only one dose. Most infants either had a high-risk condition (i.e., anatomic/functional asplenia or DiGeorge syndrome) (42.0%), or a travel indication (54.3%). The incidence rate of ED visits was 0.6/person-year (95% confidence interval [CI]: 0.5-0.8), 0.4/person-year (CI: 0.3-0.5) for hospitalizations, and 0.1/person-year (CI: 0.1-0.3) for ED to hospital transfers. Overall, 29.0% of recipients had an incident diagnosis in the ED or hospital setting. Fever and acute upper respiratory infections were the most common diagnoses, with 46 out of 47 diagnoses occurring among infants with high-risk conditions. CONCLUSIONS: Data from this descriptive observational study do not suggest safety concerns associated with MenACWY-CRM when used as part of clinical care of 2-23 month-old infants/toddlers indicated for vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Becerra-Culqui TA, Sy LS, Ackerson BK, et al. Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old. Vaccine. 2019. PMID: 31648912. doi:10.1016/j.vaccine.2019.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。